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Abstract.
The in vitro cytotoxicities of a number of gold(I), silver(I) and copper(I) complexes containing chiral
tertiary phosphine ligands have been examined against the mouse tumour cell lines P815
mastocytoma, B16 melanoma [gold(I) and silver(I) compounds] and P388 leukaemia [gold(I)
complexes only] with many of the complexes having IC50 values comparable to that of the
reference compounds cis-diamminedichloroplatinum(ll), cisplatin, and bis[1,2-bis(diphenyl-
phosphino)ethane]gold(I) iodide. The chiral tertiary phosphine ligands used in this study include
(R)-(2-aminophenyl)methylphenylphosphine; (R,R)-, (S,S)- and (R*,R*)-l,2-phenylenebis(methyl-
phenylphosphine); and (R,R )-, (S,S)- and (R*, R’)-bis{(2-diphenylphosphinoethyl)phenyl-
phosphino}ethane. The in vitro cytotoxicities of gold(I) and silver(I) complexes containing the
optically active forms of the tetra(tertiary phosphine) have also been examined against the human
ovarian carcinoma cell lines 41M and CH1, and the cisplatin resistant 41McisR, CHlcisR and
SKOV-3 tumour models. IC5o values in the range 0.01 0.04 #M were determined for the most
active compounds, silver(I) complexes of the tetra(tertiary phosphine). Furthermore, the chirality of
the ligand appeared to have little effect on the overall activity of the complexes: similar IC50 data
were obtained for complexes of a particular metal ion with each of the stereoisomeric forms of a
specific ligand.
Introduction.
Bis(ditertiary phosphine) complexes of gold(I), silver(I) and copper(I) have attracted much interest
over the past decade as certain of these complexes have been shown to display antitumour
activities comparable to cis-diamminedichloroplatinum(ll), cisplatin, for example, bis[1,2-
bis(diphenylphosphino)ethane]gold(I) chloride, [Au(dppe)2]CI, and its silver(I) and copper(I)
derivatives. The mode of action of these complexes is not known but it is believed to be quite
different to that of cisplatin. The complex [Au(dppe)2]CI has been shown to inhibit DNA, RNA and
protein synthesis; to cause DNA single strand breaks; and to induce mitochondrial damage in
hepatocytes. Indeed, despite the early promise of [Au(dppe)2]CI and its derivatives, the
compounds have subsequently been shown to be too toxic for clinical use due to side-effects
related to the disruption of mitochondrial function in hepatocytes. 2,3
We have recently synthesised a number of related gold(I), silver(I) and copper(I) complexes
containing the substituted (2-aminophenyl)phosphines AMPP [(+)-(2-aminophenyl)methylphenyl-
phosphine] and ADPP [(2-aminophenyl)diphenylphosphine] and investigated their in vitro cytotoxic
properties against three mouse tumour cell lines, P815 mastocytoma, B16 melanoma and P388
leukaemia.4 Certain of these complexes exhibited antiproliferative properties comparable to those
of the two reference compounds cisplatin and [Au(dppe)2]l. Furthermore, the complexes
[Au(ADPP)2]PF6 and [Au{(+)-AMPP}2]PF6 were shown to rapidly accumulate in mitochondria by
virtue of their lipophilic, cationic nature and to inhibit the activity of ATP synthase leading to rapid
cell death. 5
In this paper we report on the in vitro cytotoxic properties of a range of gold(I), silver(I) and
copper(I) complexes containing chiral tertiary arsine and phosphine ligands against the P815
tumour cell line. IC50 values have also been determined for certain of these complexes against the
tumour cell lines B16, P388, 41M, and CH1, and the cisplatin resistant 41McisR, CHlcisR and
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SKOV-3 tumour models. While the chirality of platinum-based antitumour agents is known to have
a dramatic influence on their activity,6 this effect has not previously been investigated for gold(I),
silver(I) or copper(I) complexes containing tertiary phosphine ligands.
aterials and Methods.
(a) Syntheses. The ligands (+)-(2-aminophenyl)methylphenylphosphine,7 (R*,R*)-l,2-phenylene-
bis(methylphenylphosphine)8 and (R*, R*)-1,2-bis{(2-diphenylphosphinoethyl)phenylphosphino}-
ethane9 were synthesised and resolved following literature procedures. The complexes containing
(R,R)-, (S,S)- and (R*,R*)-dias or-diph [M Ag(I) or Cu(I)]1 and (R,R)- and (S,S)-tetraphos [M
Au(I), Ag(I) or Cu(I)]9 were prepared as previously described in the literature. The synthesis of
[Au2{(R*,R*)-tetraphos}2](PF6)2, [Au2{(R*,S*)-tetraphos}2](PF6)2, [Ag2{(R*,R*)-tetraphos}2]-(PF6)2,
and [Cu{(R*,R*)-tetraphos}]PF6 will be reported elsewhere.11
Synthesis of [L-2]-Bis[(R)-(2-aminophenyl)methylphenylphosphine]gold(I) Iodide Ethanol Solvate,
[Au{(R)-AMPP}2]I. The complex was prepared in a similar manner to that described for [Au{(+)-
AMPP}2]I.4 A solution of the optically active ligand (R)-AMPP (0.17 g, 0.79 mmol) in ethanol (5
mL) was added to a solution of tetra-n-butylammonium diiodoaurate(I) (0.27 g, 0.39 mmol) in
ethanol (15 mL) with stirring. The white crystalline product was filtered off, washed with ethanol
and dried in vacuo (0.24 g, 83%), m.p. 172 C. (Found: C, 42.3; H, 4.2; N, 3.3. Calc. for
C28H34AulN2OP2" C, 42.0; H, 4.3; N, 3.5%). 1H NMR (CDCI3): 2.26 (d 6 H, 2JmH 8.5 Hz,
PMe), 4.31 (s, 4 H, NH2), 6.63-7.67 (m, 18 H, aromatics). 31p-{H} NMR (CDCI3): 5 11.1 (s, 2 P).
AM (MeNO2): 92 cm2 S mol-1; AM (MeCN): 92 cm2 S mo1-1.
Synthesis of [T-4]-Bis[(R*,R*)- 1,2-phenylenebis(methylphenylphosphino)benzene]gold(I) Iodide,
[Au{(R*,R*)-diph}2]l. Tetra-n-butylammonium diiodoaurate(I) (0.22 g, 0.32 mmol) was dissolved in
ethanol (20 mL) and the ligand (R*,R*)-diph (0.20 g, 0.62 mmol) was slowly added with stirring.
The solution was stirred for 30 min and then the solvent was removed by evaporation. The residue
was dissolved in acetone (5 mL) and diethyl ether was added dropwise to give a white crystalline
product which was filtered off, washed with diethyl ether and dried in vacuo (0.24 g, 80%), mp.5 160 oc (Found: C, 50.0; H, 4.3. Calc. for C40H40AulP4" C, 49.6; H, 4.2%). 1H NMR (CDCI3).
2.27 (s, 12 H, PMe), 7.12-7.53 (m, 28 H, aromatics). 3P-{H} NMR (CDCI3)’5 4.6 (s, 4 P). M
(MeNO2): 93 cm2 S mol-1; AM (MeCN): 94 cm2 S mo1-1.
Synthesis of [T-4]-Bis[(R,R)- 1,2-phenylenebis(methylphenylphosphino)benzene]gold(I) Iodide,
[Au{(R,R)-diph}2]l. Prepared as for [Au{(R*,R*)-diph}2]l except using tetra-n-butylammonium
diiodoaurate(I) (0.16 g, 0.23 mmol) and the ligand (R,R)-diph (0.15 g, 0.47 mmol). The product
was recrystallised from acetone (3 mL) by the dropwise addition of diethyl ether to give white
crystals (0.18 g, 82%), m.p. 160 C. (Found: C, 49.7; H, 4.3. Calc. for C40H40AulP4: C, 49.6; H,
4.2%). 1H NMR (CDCI3) and 31p-{1H} NMR (CDCI3)" identical to that recorded for [Au{(R*,R*)-
diph}2]l. AM (MeNO2): 93 cm2 S moll; AM (MeCN)’ 94 cm2 S mo1-1.
Synthesis of [T-4]-Bis[(S,S)- 1,2-phenylenebis(methylphenylphosphino)benzene]goid(I) Iodide,
[Au{(S,S)-diph}2]l. Prepared as for [Au{(R*,R*)-diph}2]l except using tetra-n-butylammonium
diiodoaurate(I) (0.16 g, 0.23 mmol) and the ligand (S,S)-diph (0.15 g, 0.47 mmol). The product
was obtained as white crystals after recrystallisation from acetone diethyl ether (0.21 g,94%),
m.p. 160 C. (Found" C, 49.3; H, 4.1. Calc. for C40H40AulP4: C, 49.6; H, 4.2%). H NMR
(CDCI3) and 31p-{1H} NMR (CDCI3): identical to that recorded for [Au{(R*,R*)-diph}2]l. AM
(MeNO2): 93 cm2 S moll; AM (MeCN): 94 cm2 S mo1-1.
Synthesis of [T-4]-Tris[(R)-(2-aminophenyl)methylphenylphosphine]silver(I) Hexafluorophosphate,
[Ag{(R)-AMPP}3]PF6. The complex was prepared in a similar manner to that described for [Ag{(+)-
AMPP}3]PF6.4 A solution of (R)-AMPP (0.09 g, 0.42 mmol) in ethanol (5 mL) was added dropwise
to a solution of silver nitrate (0.02 g, 0.12 mmol) in ethanol (25 mL). The solution was filtered, the
solvent removed by evaporation, the residue redissolved in dichloromethane (10 mL) and a
solution of NH4PF6 (0.20 g, 1.22 mmol) in water (5 mL) added. The organic layer was separated
off, dried over anhydrous MgSO4, filtered and the solvent again removed by evaporation. The
residue was redissolved in methanol (5 mL) and gave a white crystalline product on standing. The
product was collected, washed with diethyl ether (5 mL), dried in vacuo and stored in the dark
(0.09 g, 82%), m.p. 168 C. (Found: C, 52.0; H, 4.4; N, 4.5. Calc. for C39H42AgF6N3P4: C, 52.1;
H, 4.7; N, 4.7%). 1H NMR (CDCI3): 51.82 (br s, 9 H, PMe), 4.75 (s, 6 H, NH2), 6.80-7.54 (m, 27
H, aromatics). 3P-{H} NMR (CDCI3):5 -22.5 (s, 3 P). AM (MeNO2): 83 cm2 S mol’; AM
(MeCN): 84 cm2 S mo1-1.
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(b) Biological procedures and materials. (i) Mouse tumour cell lines: P815 mastocytoma cells were
cultured in Eagle’s Minimum Essential Medium F15 with 10% foetal bovine serum; B16 cells in
McCoy’s medium RPMI 1640 with 10% foetal bovine serum; and P388 leukaemia cells in
Dulbecco’s Modified Eagle Medium H16 with 10% horse serum (herein EC10). All cells were
cultured and incubated in a Forma Scientific Infrared CO2 incubator at 37 oC in 5% CO2. Cell
suspensions were centrifuged using a Jouan centrifuge model CR 4 22. Linbro 96 round bottom
well tissue culture plates were used for the thymidine incorporation assay. Cells were harvested
using a Pharmacia Version 1.02 Micro Cell Harvester and incorporated thymidine was counted
using a Pharmacia 1205 Betaplate liquid scintillation counter. Thymidine incorporation assays
were performed following a literature procedure. 12 The compounds tested were dissolved in
dimethylsulfoxide (0.2 mh) to give a concentration of 0.02 M and then diluted to 2 x 10-5 M using
EC10.
(ii) Human ovarian carcinoma cell lines: The biological
properties of the CH1,41M and SKOV-3 cell lines have been described previously. 13,14 The cell-
lines were grown as monolayers in Dulbecco’s modified Eagle plus10% foetal calf serum, 100 lg
mL-1 streptomycin, 100 #g mL1 penicillin and 2 mM glutamine in a 5% CO2 atmosphere. The cell
lines were checked regularly for mycoplasma infection. Cytotoxicity assessment was undertaken
using the sulphorhodamine B assay as described previously. 14 The complexes were dissolved in
dimethylsulfoxide, diluted in distilled water and added to the cultures at concentrations ranging
from 0.005 to 5 l.tM in quadruplicate. The final concentration of dimethylsulfoxide in the culture
medium was < 0.5%. The cells were exposed to the drug containing medium for 96 h. The IC5o
values were determined as the drug concentration reducing absorption (564 nm) of
sulphorhodamine B-stained wells to 50% of that of the control wells.
Results.
Complexes. A number of univalent gold, silver and copper complexes have been utilised in the
present study containing the ligands (R)-(2-aminophenyl)methylphenylphosphine (AMPP); (R,R)-,
(S,S)- and (R*,R*)-l,2-phenylenebis(methylphenylphosphine) (diph) and their arsenic analogues
(dias); and (R,R)-, (S,S)-, (R*,R*)- and (R*,S*)-bis{(2-diphenylphosphinoethyl)phenylphosphino}-
ethane (tetraphos).l-
NH2 p,,..
p
AMPP diph
(Only one enantiomer of each ligand is shown.)
The complexes that were used in this work are listed in Tables 1-4. We have previously described
the preparation and characterisation of many of these complexes.9,1 Complexes containing (R)-
AMPP were prepared in a similar fashion to that reported for their racemic analogues.4 Gold(I)
compounds of diph were synthesised by reacting two equivalents of the appropriate form of the
ligand with NBu4[Aul2]. We have previously prepared the corresponding hexafluorophosphate
salts via an alternate route. 15
1 No gold(I) complexes of dias; silver(I) compounds of (R,R)-dias, (R,R)-diph and (R*,S*)-
tetraphos; and copper(I) complexes of (R)-AMPP, (R*,S*)-tetraphos and (S,S)-diph were studied in
this work.
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Biological Studies. The in vitro cytotoxic properties of the gold(I), silver(I) and copper(I)
complexes have been assessed by measuring their effect on proliferation of the mouse tumour cell
lines P815 mastocytoma, B16 melanoma [gold(I) and silver(I) compounds] and P388 leukaemia
[gold(I) complexes only].
Table 1. IC5o values for gold(I) complexes and cisplatin against P815
mastocytoma, B16 melanoma, and P388 leukaemia tumour models
Complex IC5o (pM)
P815 B16 P388
[Au{(+)-AMPP}2]I4 9.25 2.60 5.80
[Au{(R)-AMPP}2]I 9.00 3.00 5.50
[Au{(R*,R*)-diph}2]l 0.75 5.00 0.20
[Au{(R,R)-diph}2]l 0.90 4.70 1.10
[Au{(S,S)-diph}2]l 2.45 3.50 2.30
[Au2{(R*, R*)-tetraphos}2](PF6)2 0.87 0.55 0.60
[Au(dppe)2] 14 0.22 5.20 0.10
cis-[PtCI2(NH3)2]4 14.50 0.901 5.00
Table 2. IC50 values for silver(I) complexes against P815 mastocytoma
and B16 melanoma mouse tumour cell models
Complex IC5o (a)
[Ag{(+)-AMPP}3]PF64
[Ag{(R)-AMPP}3]PF6
[Ag{( R*,R *)-d ph}2]PF6
[Ag{( S,S)-d ph}2]PF6
[Ag{(R*, R*)-dias}2]PF6
[Ag{( S,S)-dias}2]PF6
[Ag2{(R*, R*)-tetraphos}2](PF6)2
P815 B16
9.50 5.O0
9.25 5.00
0.14 4.00
1.62 4.30
0.75 1.30
0.32 1.40
0.04
Table 3. IC50 values for copper(I) complexes and
the free ligands against P815 mastocytoma mouse
tumour cell model
Complex
[Cu{(+)-AMPP}2]PF64
[Cu{(+)-AMPP}3]PF64
[Cu{(R*,R*)-diph}2]PF6
[Cu{(R,R)-diph}2]PF6
[Cu{(R*,R*)-dias}2]PF6
[Cu{(R,R)-dias 2]PF6
[Cu{(S, S)-dias}2]PF6
[Cu{(R *,R *)-tetraphos}]PF6
[Cu{(R, R)-tetraphos}]PF6
[Cu{(S, S)-tetraphos}]PF6
ICso (M)
49.00
6.00
0.14
1.45
0.57
0.52
0.35
0.15
0.16
0.14
Ligand
(R*,R*)-diph
(R,R)-diph
(S,S)-diph
(S, S)-tetraphos
0.30
0.27
0.49
O.85
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The IC50 values (concentrations resulting in 50% inhibition of labelled thymidine) for these
complexes and the reference compounds cisplatin and [Au(dppe)2]l are given in Tables 1-3. IC5o
values for the ligands (R*,R*)-, (R,R)- and (S,S)-diph, and (S,S)-tetraphos against the P815
mastocytoma cell line are also included in Table 3. The in vitro cytotoxicities of gold(I) and silver(I)
complexes containing the optically active or meso [for Au(I) only] forms of the tetra(tertiary
phosphine) tetraphos have also been examined against the human ovarian carcinoma cell lines
41M and CH1, the acquired cisplatin resistant 41McisR and CHlcisR tumour models, and the
intrinsically cisplatin resistant SKOV-3 line. IC5o values (determined via a sulphorhodamine B
assay) for these complexes are given in Table 4.
Table 4. IC50 values for gold(I) and silver(I) complexes containing (R,R)-, (S,S)-, and (R*,S*)-
tetraphos against P815, 41 M, 41McisR, SKOV-3, CH1 and CHlcisR tumour cell lines
IC5o (IM)
Complex P815 41M 41McisR SKOV-3 CH1 CHlcisR
[Au2{ R, R)-tetraphos}2](PF6)2 0.82
[Au2{(S,S)-tetraphos}2](PF6)2 0.95
[Au2{(R*,S *)-tetraphos}2](PF6)2
[Ag2{(R,R)-tetraphos}2](PF6)2
[Ag2{(S,S)-tetraphos}2](PF6)2
0.42 0.55 0.47 0.40 0.20
0.39 0.43 0.45 0.34 0.16
0.35 0.47 0.30 0.31 0.15
0.03 0.029 0.021 0.052 0.016 0.015
0.02 0.029 0.022 0.077 0.016 0.012
Discussion.
Nature of Complexes. The structures of certain of the complexes used in this work have been
confirmed by X-ray analysis.4, 9 Apart from the gold(I)complex of (R)-AMPP, viz. [Au{(R)-
AMPP}2]I, which is believed to have a linear geometry about the metal centre with the ligands
bound in a monodentate fashion via the phosphorus donor atom,4 in all other cases a tetrahedral
stereochemistry prevails. The complex [Ag{(R)-AMPP}3]PF6 is believed to contain one bidentate
ligand and two ligands bound in a monodentate fashion via the phosphorus donor atom. A similar
structure has been proposed for related complexes of the type [ML3]PF6 [where M Cu(I) or Ag(I);
and L (2-aminophenyl)diphenylphosphine, ADPP, or (+)-AMPP].4 Gold(I) and silver(I) complexes
of tetraphos are dimeric in the solid state, they form bimetallic helicates having double-helical or
side-by-side helical structures.9
All of the complexes containing (R)-AMPP, dias or diph undergo rapid ligand exchange reactions in
solution with the gold(I) compounds of the latter being the least kinetically labile.4, Ligand
exchange reactions for complexes containing the tetra(tertiary phosphine) appear to be much
slower, for example, no exchange between the gold(I) complexes and added free ligand in d6-
DMSO was observed in the 31p-{1H} NMR spectra. Molar conductance measurements on gold(I),
silver(I) and copper(I) complexes of tetraphos in acetonitrile, however, indicate that an equilibrium
between monomeric and dimeric forms probably exists in solution.9
Biological Studies. As previously noted, 1,4 the nature of the metal ion and the counterion made
very little difference to the cytotoxicity of the complexes. The silver(I) complexes of tetraphos were
the exception. They exhibited significantly higher activities towards the P815 melanoma cell line
than their gold(I) and copper(I) counterparts. This trend is not confined to one cell line but is
clearly apparent in all of the cell lines tested including the cisplatin resistant models 41McisR,
CHlcisR and SKOV-3. IC50 values in the range 0.01 0.04 #M were determined for the silver(I)
complexes of tetraphos. They are the most active of the compounds utilised in the present study.
Furthermore, the cytotoxicities of many of the complexes are comparable to that of cis-diammine-
dichloroplatinum(ll), cis-[PtCI2(NH3)2], and bis[1,2-bis(diphenylphosphino)ethane]gold(I)iodide,
[Au(dppe)2]l. Those containing the quadridentate tetra(tertiary phosphine) tetraphos were
generally found to be more active than those incorporating the bidentate di(tertiary phosphines)
diph and dppe, which in turn exhibited greater cytotoxicities than compounds with AMPP ligands.
A similar trend is generally observed with respect to the kinetic stabilities of these complexes. The
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data, however, do not reflect differences in kinetic stability based on the nature of the metal ion.
The free tertiary phosphines themselves are also cytotoxic but generally to a significantly lesser
extent than their metal complexes.
Complexes containing tertiary arsines are also active. The copper(I) and silver(I) compounds
containing dias had a similar effect on the proliferation of P815 melanoma cells as their diph
counterparts. The complexes of dias are significantly more labile than their diph analogues.0
The chirality of the ligand had no apparent effect on the cytotoxicity of the complex. In most cases
similar IC5o data were recorded irrespective of the isomeric form of the ligand coordinated to the
metal ion. A ten-fold difference in activity was observed between [Ag{(R*,R*)-diph}2]PF6 and
[Ag{(S,S)-diph}2]PF6 against the P815 but not the B16 cell lines. This data supports the notion that
the biological target of these complexes is different to that of cisplatin. In the case of chiral
platinum-based complexes a significant difference in activity has been observed between the two
enantiomers; those containing the (R,R) antipode of a range of optically active diamines were more
cytotoxic than either the (S,S) or racemic forms of the corresponding ligands.6
The IC5o values reported in this work were typically determined over a period of 22 h: treated
samples were incubated for 18 h prior to the addition of 3H-thymidine and then further incubated
for 4 h. The data reported in Table 4 (except against P815) was determined over a period of 96 h
using a sulphorhodamine B assay. As we reported previously for gold(I) complexes containing (+)-
AMPP, (R*,R*)-tetraphos, dppe or ADPP;5 a different reaction profile was observed when the
thymidine incor..poration assay was performed using the minimum time requirement for the
experiment, i.e. H-thymidine was added after 0.25 h to the treated samples and then incubated for
a further 0.5 h. No significant inhibition of DNA synthesis in the murine P388 leukaemia cell line
was observed for cisplatin or [Au2(tetraphos)2]2+ under these conditions. Complete inhibition of
DNA synthesis takes 20 h at a concentration of 10M and 100M for [Au2(tetraphos)2]2+ and
cisplatin, respectively. On the other hand, rapid inhibition of DNA synthesis was observed for
gold(I) complexes containing AMPP, dppe or ADPP and furthermore their dose response did not
substantially change over 24 h indicating that their effect was rapid and complete within h.
These complexes were also shown to cause a rapid increase in the mitochondrial membrane
potential in intact P388 leukaemia cells which correlates with their early effect on DNA synthesis.
The gold(I) complex of (R*,R)-tetraphos, but not cisplatin, was also shown to cause an increase in
the mitochondrial membrane potential when the experiment was performed over a period of 4 h.
This mitochondrial activity has been shown to arise from inhibition of ATP synthase by the gold(I)
complexes.5
The IC50 data reported here further corroborate these earlier findings i.e. the primary target of
gold(I), silver(I) and copper(I) complexes containing tertiary phosphine ligands is not DNA. A much
more dramatic difference in IC5o values would have been expected for complexes containing
different stereoisomeric forms of the same ligand, if this was the case. Rather these gold(I)
complexes [and presumably their silver(I) and copper(I) analogues] act by rapid accumulation in
mitochondria by virtue of their lipophilic cationic nature followed by inhibition of the ATP synthase
which ultimately results in the observed inhibition of cellular proliferation.
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